GGrantIndex
← Leaderboards

Andrea B Troxel

Columbia University Health Sciences

$185,878,739
Attributed
$698,216,013
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $452.5M · FY201125
$500M$375M$250M$125M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$698,216,013 · 10

By mechanism

OT2$650,978,035 · 1
U24$28,175,516 · 2
U10$13,369,970 · 1
R33$2,221,264 · 1
P30$1,248,589 · 1
U54$1,168,132 · 1

Top collaborators

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Design

Research focus

DesignData ManagementClinical Trials DesignClinical TrialsStatistical Data InterpretationBiometryResearch PersonnelReportingMonitorRandomizedHuman ResourcesData CollectionEnsureResearch DesignResourcesProceduresProtocols DocumentationQuality ControlData AnalysesCommunitiesTrainingFoundationsBioinformaticsData Set

Grant awards (51)

2/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial) –DCC$570,142
U24 · FY2025 · HL · contact PI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$90,000
OT2 · FY2025 · HL
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$109,438,442
OT2 · FY2024 · HL
EPPIC-NET DCC - Supplement$3,941,104
U24 · FY2024 · NS · contact PI
2/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial) –DCC$540,232
U24 · FY2024 · HL · contact PI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$59,963,139
OT2 · FY2023 · HL
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$2,127,591
U10 · FY2023 · EY
2/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial) –DCC$539,119
U24 · FY2023 · HL · contact PI
EPPIC-NET DCC$95,971
U24 · FY2023 · NS · contact PI
EPPIC-NET DCC$1
U24 · FY2023 · NS · contact PI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$33,203,136
OT2 · FY2022 · HL
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$679,231
U10 · FY2022 · EY
EPPIC-NET DCC$663,520
U24 · FY2022 · NS · contact PI
2/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial) –DCC$622,751
U24 · FY2022 · HL · contact PI
Statistical Methods to Jointly Model Multiple Pain Outcome Measures$95,971
U24 · FY2022 · NS · contact PI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core$448,283,318
OT2 · FY2021 · HL
EPPIC-NET DCC$3,425,553
U24 · FY2021 · NS · contact PI
EHR nudges: Development and testing of a behavioral economics electronic health record module$740,817
R33 · FY2021 · AG · contact PI
EPPIC-NET DCC$63,657
U24 · FY2021 · NS
EPPIC-NET DCC$21,220
U24 · FY2021 · NS
EPPIC-NET DCC$2,959,226
U24 · FY2020 · NS
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$1,985,974
U10 · FY2020 · EY
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$1,424,768
U10 · FY2020 · EY
EPPIC-NET DCC - Revision$1,333,195
U24 · FY2020 · NS
EHR nudges: Development and testing of a behavioral economics electronic health record module$740,817
R33 · FY2020 · AG · contact PI
EPPIC-NET DCC$13,303,854
U24 · FY2019 · NS
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$3,278,651
U10 · FY2019 · EY
EHR nudges: Development and testing of a behavioral economics electronic health record module$739,630
R33 · FY2019 · AG · contact PI
Biostatistics Core$7,211
P30 · FY2019 · CA · contact PI
Biostatistics Core$5,767
P30 · FY2019 · CA · contact PI
Biostatistics Core$3,626
P30 · FY2019 · CA · contact PI
Biostatistics Core$1,106
P30 · FY2019 · CA · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$3,873,755
U10 · FY2018 · EY
EHR nudges: Development and testing of a behavioral economics electronic health record module$243,238
R21 · FY2018 · AG · contact PI
Biostatistics Core$9,405
P30 · FY2018 · CA · contact PI
Biostatistics Core$604,005
P30 · FY2017 · CA · contact PI
EHR nudges: Development and testing of a behavioral economics electronic health record module$215,774
R21 · FY2017 · AG · contact PI
Biostatistics Core$617,469
P30 · FY2016 · CA · contact PI
Bioinformatics Core$238,198
U54 · FY2015 · CA · contact PI
Bioinformatics Core$233,047
U54 · FY2014 · CA · contact PI
Bioinformatics Core$224,250
U54 · FY2013 · CA · contact PI
Bioinformatics Core$228,716
U54 · FY2012 · CA · contact PI
Bioinformatics Core$243,921
U54 · FY2011 · CA · contact PI
CLINICAL TRIALS WITH QUALITY OF LIFE AND COMPLIANCE DATA$115,088
R01 · FY2002 · CA
Core--Biostatistics, Epidemiology, and Data Management Facility$0
P50 · FY2002 · AT
CLINICAL TRIALS WITH QUALITY OF LIFE AND COMPLIANCE DATA$115,088
R01 · FY2001 · CA
Core--Biostatistics, Epidemiology, and Data Management Facility$0
P50 · FY2001 · AT
Core--Biostatistics, Epidemiology, and Data Management Facility$0
P50 · FY2001 · AT
Core--Biostatistics, Epidemiology, and Data Management Facility$0
P50 · FY2001 · AT
Core--Biostatistics, Epidemiology, and Data Management Facility$250,231
P50 · FY2000 · AT
CLINICAL TRIALS WITH QUALITY OF LIFE AND COMPLIANCE DATA$115,088
R01 · FY2000 · CA